Intellectual property. Challenges to India's pharmaceutical patent laws.
作者信息
Sampat Bhaven N, Shadlen Kenneth C, Amin Tahir M
机构信息
Health Policy and Management, Columbia University, New York, NY 10032, USA.
出版信息
Science. 2012 Jul 27;337(6093):414-5. doi: 10.1126/science.1224892. Epub 2012 Jul 5.
PMID:22767892
Abstract
摘要
相似文献
1
Intellectual property. Challenges to India's pharmaceutical patent laws.知识产权。印度制药专利法面临的挑战。
Science. 2012 Jul 27;337(6093):414-5. doi: 10.1126/science.1224892. Epub 2012 Jul 5.
2
Big Pharma vs India’s Patent Office.大型制药公司与印度专利局的较量
Pharm Pat Anal. 2012 Nov;1(5):529. doi: 10.4155/ppa.12.72.
3
India's rejection of Novartis's patent is but a small step in the right direction.印度拒绝诺华公司的专利申请只是朝着正确方向迈出的一小步。
BMJ. 2013 Apr 17;346:f2412. doi: 10.1136/bmj.f2412.
4
Intellectual property. Balancing innovation and access: patent challenges tip the scales.知识产权。平衡创新与获取：专利挑战使天平倾斜。
Science. 2009 Oct 16;326(5951):370-1. doi: 10.1126/science.1176116.
5
Novartis challenges India's drug patent laws in Supreme Court.诺华在最高法院对印度的药品专利法提出质疑。
BMJ. 2012 Feb 21;344:e1279. doi: 10.1136/bmj.e1279.
6
Legal challenge to India's patent laws threatens access to generic drugs, says charity.
BMJ. 2011 Sep 9;343:d5753. doi: 10.1136/bmj.d5753.
7
India's patent case victory rattles Big Pharma.
Lancet. 2013 Apr 13;381(9874):1263. doi: 10.1016/s0140-6736(13)60826-0.
8
India's patent laws under pressure.
Lancet. 2012 Sep 15;380(9846):e2-4. doi: 10.1016/s0140-6736(12)61513-x.
9
Taking TRIPS to India--Novartis, patent law, and access to medicines.前往印度的《与贸易有关的知识产权协定》之行——诺华公司、专利法与药品可及性
N Engl J Med. 2007 Feb 8;356(6):541-3. doi: 10.1056/NEJMp068245.
10
India's new patent laws may still hurt generic drug supplies.
Lancet. 2005;365(9468):1378. doi: 10.1016/S0140-6736(05)66356-8.
引用本文的文献
1
Trade and investment liberalization and Asia's noncommunicable disease epidemic: a synthesis of data and existing literature.贸易与投资自由化及亚洲的非传染性疾病流行：数据与现有文献综述
Global Health. 2014 Sep 12;10:66. doi: 10.1186/s12992-014-0066-8.
Zotero 插件